Tempus Expands Strategic Collaboration with Bristol Myers Squibb to Enhance the Probability of Success Across Clinical Development Programs In Oncology and Neuroscience
Go back to Tempus Expands Strategic Collaboration with Bristol Myers Squibb to Enhance the Probability of Success Across Clinical Development Programs In Oncology and Neuroscience| Bristol-Myers Squibb (NYSE: BMY) | Delayed: 54.70 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $54.70 | 52 Week High | $77.12 | |||
| Open | $54.70 | 52 Week Low | $49.03 | |||
| Day High | $54.70 | P/E | 35.52 | |||
| Day Low | $54.70 | EPS | $1.54 | |||
| Volume | 4,158 | |||||
| StemCells, Inc. (NASDAQ: TEM) | Delayed: 47.85 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $47.85 | 52 Week High | $0.45 | |||
| Open | $47.85 | 52 Week Low | $0.37 | |||
| Day High | $47.85 | P/E | N/A | |||
| Day Low | $47.85 | EPS | $-0.31 | |||
| Volume | 71,895 | |||||
